Zydus Lifesciences shares slipped modestly after the company announced that the US Food and Drug Administration completed its inspection of the New Jersey office with zero findings.
The inspection, conducted between September 22 and 25, 2026, covered the firm’s pharmacovigilance and post‑marketing surveillance system and was carried out on‑site at the U.S. site.
Earlier in August, Zydus secured final USFDA approval for its generic Ascorbic Acid Injection, a product with annual U.S. sales of roughly $11.6 million. The approval covers two strengths – 25,000 mg/50 mL and 5,000 mg/10 mL – each at a concentration of 500 mg/mL and qualifies as a Competitive Generic Therapy, potentially granting 180‑day exclusivity.
Zydus plans to manufacture the injection at its U.S.‑FDA‑approved facility in Jarod, near Vadodara, Gujarat, and market it through Zydus Pharmaceuticals Inc. The company’s filing under SEBI Regulation 30 of the 2015 regulations confirms compliance with domestic disclosure requirements.
Moving forward, Zydus will monitor regulatory developments and likely focus on scaling U.S. sales of the newly approved generic, while investors will watch for any guidance on the timing of commercial launch and potential impact on revenue.